ORGANOGENESIS HOLDINGS INC. Provision for Other Credit Losses
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Provision for Other Credit Losses of -$2.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForOtherCreditLosses · last filed 2026-08-06
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for the quarter ending 2026-06-30 was $984.00K, a 56.13% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for the quarter ending 2026-03-31 was -$3.96M, a 553.49% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for the quarter ending 2025-12-31 was $2.81M, a 1206.98% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for the quarter ending 2025-09-30 was $2.29M, a 35.25% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for fiscal 2025 was $8.21M, a 108.56% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for fiscal 2024 was $3.94M, a 203.62% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for fiscal 2023 was $1.30M, a 27.18% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. provision for other credit losses for fiscal 2022 was $1.78M, a 40.61% decline from fiscal 2021.
| Period end | Provision for Other Credit Losses 3 month | Provision for Other Credit Losses 6 month | Provision for Other Credit Losses 9 month | Provision for Other Credit Losses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $984.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$2.98M 10-Q · filed 2026-08-06 | -$165.00K derived: sum of 3 quarters · filed 2026-08-06 | $2.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.96M 10-Q · filed 2026-05-07 | -$1.15M derived: sum of 2 quarters · filed 2026-05-07 | $1.14M derived: sum of 3 quarters · filed 2026-05-07 | $3.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.10M derived: sum of 2 quarters · filed 2026-02-26 | $7.34M derived: sum of 3 quarters · filed 2026-08-06 | $8.21M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.53M derived: sum of 2 quarters · filed 2026-08-06 | $5.40M 10-Q · filed 2025-11-06 | $5.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.12M 10-Q · filed 2026-08-06 | $3.33M derived: sum of 3 quarters · filed 2026-08-06 | $5.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $873.00K 10-Q · filed 2026-05-07 | $1.09M derived: sum of 2 quarters · filed 2026-05-07 | $2.78M derived: sum of 3 quarters · filed 2026-05-07 | $3.84M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.91M derived: sum of 2 quarters · filed 2026-02-26 | $2.97M derived: sum of 3 quarters · filed 2026-02-26 | $3.94M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.75M derived: sum of 2 quarters · filed 2025-11-06 | $3.72M 10-Q · filed 2025-11-06 | $3.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.03M 10-Q · filed 2025-08-07 | $2.01M derived: sum of 3 quarters · filed 2026-02-26 | $3.14M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $968.00K 10-Q · filed 2025-05-08 | $945.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.08M derived: sum of 3 quarters · filed 2026-02-26 | $2.02M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.11M derived: sum of 2 quarters · filed 2026-02-26 | $1.05M derived: sum of 3 quarters · filed 2026-02-26 | $1.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.08M derived: sum of 2 quarters · filed 2024-11-12 | $1.32M 10-Q · filed 2024-11-12 | $2.25M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$53.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $190.00K 10-Q · filed 2024-08-08 | $1.12M derived: sum of 3 quarters · filed 2025-02-27 | $1.85M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $243.00K 10-Q · filed 2024-05-09 | $1.17M derived: sum of 2 quarters · filed 2025-02-27 | $1.90M derived: sum of 3 quarters · filed 2025-02-27 | $1.98M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $926.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.66M derived: sum of 2 quarters · filed 2025-02-27 | $1.74M derived: sum of 3 quarters · filed 2025-02-27 | $1.78M 10-K · filed 2025-02-27 |
| 2022-09-30 | $733.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $815.00K derived: sum of 2 quarters · filed 2023-11-09 | $855.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $122.00K 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $40.00K 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | $3.00M 10-K · filed 2024-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |